Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2022-12-19 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-12-19 English
FORM 4
Director's Dealing
2022-12-19 English
FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus describing the securities offered by selling securityholders, details about the company, risk factors, and other offering-related information. This is a capital markets filing related to fundraising and securities offering, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a capital raising filing.
2022-12-16 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 14, 2022. It details a private placement of common stock shares by BioCardia, Inc., including the number of shares, price, investors involved, and the intended use of proceeds. The document also references a Securities Purchase and Registration Rights Agreement and includes an exhibit of the agreement form. The content focuses on a financing transaction and capital raising activity rather than financial results, management changes, or other report types. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (6158 characters) supports it being a full report rather than a brief announcement or certification. Confidence is high due to clear references to private placement and capital raising terms.
2022-12-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by BioCardia, Inc. It announces an event on December 6, 2022, specifically the FDA approval of an IND application to initiate a clinical trial. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. The length is 3305 characters, which is relatively short and consistent with a current report announcing a specific event rather than a full financial report. The content fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like earnings release or annual report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-12-06 English
FORM 4
Director's Dealing
2022-11-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.